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A B S T R A C T
We have generated UQACi001-A, a new induced pluripotent stem cell (iPSC) line derived from skin fibroblasts of a male patient with the generalized severe
epidermolysis bullosa simplex phenotype (EBS-gen sev) and carrying the keratin 14 (K14) R125S mutation. Fibroblasts were reprogrammed using non-integrating
Sendai virus vectors. The iPSC line displayed normal molecular karyotype, expressed pluripotency markers, is capable of differentiating into three embryonic germ
layers and is genetically identical to the originating parental fibroblasts. The established iPSC model provides a valuable resource for studying the rare disease of
epidermolysis bullosa simplex and developing new therapies as DNA editing by CRISPR/Cas9 technology.
Resource table










Type of cell line iPSC
Origin Human skin cells
Additional origin info Induced pluripotent stem cell line (iPSC)
Age: 33 years old
Sex: male
Ethnicity: Canadian




Non-integrating SeV-mediated delivery of OCT4, SOX2, c-
MYC, and KLF4
Genetic Modification YES
Type of Modification Hereditary
Associated disease Epidermolysis bullosa simplex
Gene/locus Keratin14 gene (KRT14), locus 17q21.2,
Autosomal dominant mutation NM_000526.5
(KRT14):c.373C>A (K14 p.R125S)
Method of modification N/A












Ethical approval Le comité d’éthique de la recherche avec des êtres
humains de l'Université du Québec à Chicoutimi, Canada
(Approval number 602.162.05)
1. Resource utility
The iPSCs line was established from an EBS patient with the severe
missense mutation p.R125S, not reported elsewhere (Bchetnia et al.,
2012). This line might provide a cellular model to investigate the bio-
logical pathways altered by this mutation as well as to construct in vitro
3D skin models useful for novel personalized therapies.
2. Resource details
Epidermolysis bullosa simplex (EBS) is a rare skin disease char-
acterized by skin fragility and blistering upon minor mechanical
trauma. This disease is primarily caused by dominantly autosomal
mutations in the keratin 5 (KRT5) or 14 genes (KRT14). These muta-
tions lead to a collapse of the keratin cytoskeleton into cytoplasmic
protein aggregates and the appearance of the EBS phenotype. To date,
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Fig. 1. Characterization of the UQACi001-A iPSC line.
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close to 200 distinct pathogenic mutations have been identified (http://
www.interfil.org) and variants in the KRT14 gene that encodes keratin
14, are responsible for approximately 37% of all cases (Fine et al.,
2014). A particular arginine codon within the helix initiation peptide in
K14 (R125) is the most commonly mutated residue occurring in >30%
of EBS-gen-sev cases, probably because it contains a hypermutable CpG
dinucleotide. As a result, many studies in the literature reported severe
affected patients with the cysteine (TGC) or histidine (CAC) in the place
of the arginine codon (CGC) (Uitto et al., 2007). Our patient with the
EBS-gen-sev phenotype is carrying a serine (AGC) at the 125 position
(p.R125S) which is until now not reported elsewhere (Bchetnia et al.,
2012).
Here we reprogrammed primary fibroblasts obtained from a skin
biopsy of this patient (EBS21F) on iPSCs using non-integrative Sendai
virus containing the human reprogramming factors, OCT4, SOX2, C-
MYC and KLF4 (Takahashi et al., 2007) following instructions by
manufacturer. Four weeks post transduction, colonies with a typical
morphology of pluripotent stem cells appeared. These clones were
subsequently manually picked and expanded to establish feeder-free
iPSC cells (Fig. 1A). After two months’ culture, the clearance of the
virus and the exogenous reprogramming factor genes was confirmed in
the resulting UQACi001-A cell line by PCR using specific primers
(Fig. 1B). The presence of the heterozygous (K14 p.R125S) mutation
was confirmed in the iPSC line by Sanger sequencing (Fig. 1C). Plur-
ipotency was assessed by specific immunofluorescence staining for
OCT4, NANOG, SSEA4, TRA-1-60 and TRA-1-81 (Fig. 1D) as well as by
qRT-PCR for OCT4, NANOG, DNM3TB, hTERT, and TDGF (Fig. 1E). The
iPSC line showed robust expression of all tested pluripotency markers.
UQACi001-A cell line formed embryoid bodies that spontaneously dif-
ferentiated into three germ layers. Using scorecard analysis, we ob-
served expression of specific markers for ectoderm, mesoderm and
endoderm (Fig. 1F). Examination of the genomic integrity of our iPSC
line using array CGH, after six passages, showed a normal karyotype
with no gain or loss that would be detected in a traditional karyotype
(>5 MB) (Fig. 1G). STR analysis for 16 short tandem repeat markers
showed identical profiles for iPSC line with the parental fibroblasts
(available with the authors). Mycoplasma testing was negative proving
that our iPSC line is free from mycoplasma contamination (Fig. S1). The
current data proves that stable EBS-gen-sev patient specific iPSC line
have been successfully generated. UQACi001-A cell line can provide a
powerful tool for: 1) establishing an iPSC-derived skin equivalent; 2)
identifying the biological pathways altered by the R125S mutation; 3)
innovative drug screening and genome editing for EBS.
3. Materials and methods
3.1. Reprogramming patient's fibroblasts
Skin fibroblasts were cultured at 37 °C, 5% CO2, in the fibroblast
media consisted of DMEM with 10% FBS and 1% Penicillin/
Streptomycin (Thermo Fisher Scientific). 3 × 105 cells, at passage 2,
were transduced with the genome integration-free SeV virus kit
(CytoTune™−2.0, ThermoFisher Scientific) following manufacturer's
guidelines. When clones with hESC like appearance reached a sufficient
size, they were manually picked and passaged for expansion (Table 1).
The iPSCs were maintained on Matrigel (Corning) with mTeSR1
medium (StemCell Technologies™) at 37 °C and 5% CO2. Cells were
mechanically passaged every 6–8 days.
3.2. Mutation verification
Genomic DNA was extracted from primary fibroblasts and iPSCs
cells using QuickExtract™ DNA Extraction Solution (Epicentre). Primers
used for amplification and Sanger sequencing of K14p.R125S flanking
region are described in Table 2.
3.3. Immunofluorescence analysis
The pluripotency status of UQACi001-A cell line was evaluated by
immunostaining for NANOG, OCT4, SSEA4, TRA-1-60, and TRA-1-81.
Briefly, the iPSCs were fixed with 4% para formaldehyde for 15 min at
room temperature and washed with DPBS. They were permeabilized
with 0.1% Triton™X-100, and blocked with 1%BSA, 0.3% Triton™X-100
in DPBS at room temperature. Cells were then stained with specific
antibodies (Table 1). Images were captured under the fluorescent mi-
croscope (Zeiss Axio Observer Microscope).
3.4. PCR and qRT-PCR analysis
PCR was carried out on genomic DNA using HotStarTaq DNA
polymerase kit (Qiagen) using specific primers to assess the presence of
remaining Sendai virus vectors (Table 2). Total RNA was isolated from
iPSC cells using Direct-zol™ RNA miniprep and reverse transcribed into
cDNA using the Quantitect Reverse transcription kit. Pluripotency
markers expression was performed by qRT-PCR using SYBR Green I
Master hot start reaction mix. RPL13A and ACTIN were used as nor-
malization controls. Markers characterizing the three germ layers were
assessed by scorecard assay using the scorecard™ Kit 384w (Applied
Biosystems) following manufacturer's protocol (Fergus et al., 2016).
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1 panel A
Phenotype Qualitative analysis
Immunocytochemistry
Positive staining for TRA-1-81, TRA-1-60, SSEA4, OCT4 and NANOG Fig. 1 panel D
Quantitative analysis
qRT-PCR
Expression of pluripotent markers OCT4, NANOG, DNM3TB, hTERT
and TDGF
Fig. 1 panel E
Genotype Karyotype (ArrayCGH) 46XY
Resolution: 41 kb overall and 33 kb in RefSeq genes
Fig. 1 panel G
Identity STR analysis
16 sites tested, all matched submitted in archive with journal
Mutation analysis Sequencing Heterozygous for p.R125S mutation in KRT14 Fig. 1 panel C
Microbiology and virology Mycoplasma Mycoplasma testing by PCR, negative Supplementary Fig. S1
Differentiation potential Embryoid body formation Expression of genes of all three germ layers Fig. 1 panel F
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info (OPTIONAL) Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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3.5. In vitro differentiation
To evaluate the ability of UQACi001-A line to form three germ
layers, spontaneous formation of embryoid body (EB) in vitro was as-
sessed. iPSCs were harvested with accutase and plated in non-adherent
dishes in EB medium consisting of DMEM/F12, 20% KnockOut™ Serum
Replacement 1% non-essential amino acids and 1% GlutaMAX™
(ThermoFisher Scientific), 0.1 mM 2-mercaptomethanol and 50 µM
rock inhibitor Y-27632. Forming EBs were transferred, after 8 days in
suspension, onto gelatin coated plate and cultured for another 8 days.
3.6. Molecular karyotyping
Array comparative genomic hybridization (aCGH) at passage 6 was
performed for UQACi001-A cell line at the Cell Line Genetics Inc la-
boratories (Madison, WI, USA). aCGH does not detect translocations or
inversions, alterations in chromosome structure, mosaicism or poly-
ploidy.
3.7. STR analysis
This also was performed at the Cell Line Genetics Inc laboratories
(Madison, WI, USA). Briefly, fibroblasts and generated iPSCs DNA was
extracted and PCR amplification of 16 distinct STRs (vWA, D8S1179,
TPOX, FGA, D3S1358, THO1, D21S11, D8S51, Penta E, D5S818,
D13S317, D7S820, D16S539, CSF1PO, Penta D) was carried out. PCR
products were separated and analyzed.
3.8. Mycoplasma contamination detection
The absence of mycoplasma contamination was detected using
Venor®GeM Mycoplasma PCR Detection Kit (Cederlane).
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Antibody Dilution Company Cat # and RRID
Pluripotency Markers Mouse anti-OCT3/4 1:500 Santa Cruz Cat# sc-5279, RRID: AB_628051
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Secondary antibodies Rabbit anti-mouse IgG (H + L), Alexa-Fluor 488 1:500 ThermoFisher Scientific Cat# A-11001, RRID: AB_2534069
Primers
Target Forward/Reverse primer (5′−3′)


















Internal control gene (qRT-PCR) ACTB GGACTTCGAGCAAGAGATGG
AGCACTGTGTTGGCGTACAG
Internal control gene (qRT-PCR) RPL13A ACCGCCCTACGACAAGAAAA
TGCACAATTCTCCGAGTGCT
Targeted mutation analysis (Sanger sequencing) KRT14 (exon 1) AAAGTGCCAGACCCGCCC
CTGGGGAAGGGAAAGCATCT
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